-
1 Comment
CardieX Limited is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.9.
CardieX Limited's total revenue rose by 16.1% to $3M since the same quarter in the previous year.
Its net income has dropped by 5.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.0% to $-475K since the same quarter in the previous year.
Based on the above factors, CardieX Limited gets an overall score of 4/5.
Industry | Medical Devices |
---|---|
Exchange | AU |
CurrencyCode | AUD |
ISIN | AU0000015729 |
Sector | Healthcare |
Market Cap | 23M |
---|---|
PE Ratio | None |
Target Price | 0.5 |
Beta | 1.19 |
Dividend Yield | None |
CardieX Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffness indices. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables, home health, decentralized clinical trials, and remote patient monitoring. It sells its cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was founded in 1994 and is based in Sydney, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CDX.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025